Cargando…
ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer
Lipocalin 2 (Lcn2) is a promising therapeutic target as well as a potential diagnostic biomarker for breast cancer. It has been previously shown to promote breast cancer progression by inducing the epithelial to mesenchymal transition in breast cancer cells as well as by enhancing angiogenesis. Lcn2...
Autores principales: | Guo, Peng, Yang, Jiang, Jia, Di, Moses, Marsha A., Auguste, Debra T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679350/ https://www.ncbi.nlm.nih.gov/pubmed/26722369 http://dx.doi.org/10.7150/thno.12167 |
Ejemplares similares
-
Octreotide-Targeted Lcn2 siRNA PEGylated Liposomes as a Treatment for Metastatic Breast Cancer
por: Gote, Vrinda, et al.
Publicado: (2021) -
Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis
por: Guo, Peng, et al.
Publicado: (2019) -
Targeting HPV‐infected cervical cancer cells with PEGylated liposomes encapsulating siRNA and the role of siRNA complexation with polyethylenimine
por: Levine, Rachel M., et al.
Publicado: (2016) -
Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B
por: Huang, Yuanyu, et al.
Publicado: (2022) -
Inhibiting Metastatic Breast Cancer Cell Migration
via the Synergy of Targeted, pH-triggered siRNA Delivery and Chemokine
Axis Blockade
por: Guo, Peng, et al.
Publicado: (2014)